Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue
- PMID: 7679051
Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue
Abstract
The expression of type IV collagenase (M(r) 72,000) has been examined in tissues from patients with benign prostatic hyperplasia (6 patients) and varying Gleason grades of malignant prostate cancer (18 patients). Immunoperoxidase labeling indicated that expression of the type IV collagenase was weak or nonexistent in benign tissue but consistently strong in the glandular and ductal epithelial cells of prostate tumors diagnosed at Gleason grades 1-8. In moderate to advanced cancer (i.e., Gleason grades 2 to 8), invasive tumor foci in the stromal tissue produced relatively modest amounts of type IV collagenase. The normal stromal tissue (i.e., fibroblasts) uniformly failed to produce detectable levels of type IV collagenase in the 24 patients examined. Northern and quantitative slot blot hybridization assays demonstrated that collagenase type IV mRNA levels were low in benign tissue and high in malignant tumors. In contrast, the stromal cells did not express significant amounts of type IV collagenase mRNA. Enzyme-linked immunosorbent assays demonstrated that the amounts of type IV collagenase protein correlated directly with the mRNA levels in the tumor tissue. The studies suggest that type IV collagenase may be selectively overexpressed by malignant, preinvasive prostatic epithelial cells.
Similar articles
-
Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization.Am J Pathol. 1994 Mar;144(3):585-91. Am J Pathol. 1994. PMID: 8129044 Free PMC article.
-
Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.Prostate Cancer Prostatic Dis. 2004;7(4):327-32. doi: 10.1038/sj.pcan.4500750. Prostate Cancer Prostatic Dis. 2004. PMID: 15356679
-
Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma.Mod Pathol. 1993 Jan;6(1):65-8. Mod Pathol. 1993. PMID: 7678936
-
Expression of 72 kilodalton and 92 kilodalton type IV collagenase in malignant fibrous histiocytomas and dermatofibromas.Lab Invest. 1993 Sep;69(3):305-11. Lab Invest. 1993. PMID: 8397322
-
[Demonstration of thymidine phosphorylase activity in human healthy, adenomatous and cancerous prostate].Bull Cancer. 1992;79(2):151-9. Bull Cancer. 1992. PMID: 1382732 Review. French.
Cited by
-
Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.J Neurooncol. 2000;46(1):81-90. doi: 10.1023/a:1006421112839. J Neurooncol. 2000. PMID: 10896208
-
CAI: effects on cytotoxic therapies in vitro and in vivo.Cancer Chemother Pharmacol. 1994;34(6):515-21. doi: 10.1007/BF00685664. Cancer Chemother Pharmacol. 1994. PMID: 7923563
-
Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts.Br J Cancer. 1999 Jun;80(8):1137-43. doi: 10.1038/sj.bjc.6690477. Br J Cancer. 1999. PMID: 10376963 Free PMC article.
-
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.Clin Exp Metastasis. 1998 May;16(4):332-9. doi: 10.1023/a:1006513413583. Clin Exp Metastasis. 1998. PMID: 9626812
-
Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.Oncotarget. 2014 May 15;5(9):2648-63. doi: 10.18632/oncotarget.1917. Oncotarget. 2014. PMID: 24798191 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical